SEC Tracker
Get the app

BridgeBio Pharma BBIO

McCormick Frank (Director) plans to sell 1,641 BBIO shares, about $106,665

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Oct 27, 2025
  2. Broker: Merrill Lynch
  3. Shares acquired by: Stock Bonus
  4. 10b5-1 plan adopted: Aug 28, 2024

All of McCormick Frank's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 1,641 shares at $65 on Oct 27, 2025 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when BridgeBio Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
  2. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  3. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  4. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  5. Repligen RGEN public float $6.0B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.